Valenta Farm Ingavirin capsules 60 mg No. 10
Short review
Selected in the rating
16
Best rating
antiviral drugs
For adults - For children - For ARVI - For colds - Tablets / capsules
Buy Valenta Pharm Ingavirin capsules 60 mg No. 10
Characteristics of Valenta Pharm Ingavirin capsules 60 mg No. 10
Yandex.Market data
| General characteristics | |
| Drug type | medicinal product |
| Release form | capsules |
| Minimum age of use | from 7 years |
| Appointment | immunostimulating and antiviral |
| Additionally | |
| Indications for use | Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection) in children from 7 to 17 years old. Prevention of influenza A and B and other acute respiratory viral infections in children from 7 to 17 years old. |
| Contraindications | Hypersensitivity to the active substance or any other component of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Pregnancy. Breastfeeding period. Children under 7 years of age. This dosage form is not intended for use in persons 18 years of age and older (it is necessary to use dosage forms that provide the possibility of taking Ingavirin at a dose of 90 mg). |
| Application during pregnancy and lactation | Contraindicated. |
| Active substance | Pentanedioic acid imidazolylethanamide. |
| Method of administration and dosage | Inside. Regardless of the meal. For the treatment of influenza and acute respiratory viral infections, children from 7 to 17 years old are prescribed 1 capsule (60 mg) once a day. Duration of treatment is 5-7 days (depending on the severity of the condition). Taking the drug begins from the moment the first symptoms of the disease appear, preferably no later than 2 days from the onset of the disease. For the prevention of influenza and acute respiratory viral infections after contact with sick persons, children from 7 to 17 years old are prescribed 1 capsule (60 mg) 1 time per day for 7 days. |
| Side effects | Allergic reactions (rare). |
| Storage conditions | In a dark place at a temperature not exceeding 25 ° C. Keep out of the reach of children. |
| Overdose | To date, no cases of overdose of the Ingavirin drug have been reported. |
| special instructions | Concomitant use of other antiviral drugs is not recommended. It is recommended to consult a doctor before use. The drug has no mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. Ingavirin drug does not affect reproductive function, does not have embryotoxic and teratogenic effects. |
| Interaction | Experimental studies have shown that the combined use of Ingavirin with antibiotics increases the effectiveness of therapy in the model of bacterial sepsis, including that caused by penicillin-resistant strains and staphylococcus. |
| pharmachologic effect | Preclinical and clinical studies have shown the effectiveness of Ingavirin against influenza A viruses (A (H1N1), including swine A (H1Nl) pdm09, A (H3N2), A (H5N1)) and type B, adenovirus , parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including Coxsackie virus and rhinovirus. Ingavirin drug promotes accelerated elimination of viruses, shortening the duration of the disease, and reducing the risk of complications. The mechanism of action is realized at the level of infected cells by stimulating factors of innate immunity, suppressed by viral proteins.In experimental studies, in particular, it was shown that the drug Ingavirin increases the expression of the first type of interferon IFNAR receptor on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to signals from endogenous interferon. The process is accompanied by the activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It has been shown that under conditions of infection, the drug stimulates the production of the antiviral effector protein MxA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication. The drug Ingavirin causes an increase in the content of interferon in the blood to a physiological norm, stimulates and normalizes the reduced α-interferon-producing ability of blood leukocytes, stimulates γ-interferon-producing ability of leukocytes. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells, which have high killer activity in relation to cells infected with viruses. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-α), interleukins (IL-1β and IL-6)), a decrease in the activity of myeloperoxidase. The experimental toxicological studies carried out indicate a low level of toxicity and a high safety profile of the drug. According to the parameters of acute toxicity, Ingavirin belongs to the 4th class of toxicity - "Low-toxic substances" (when determining the LD50 in experiments on acute toxicity, the lethal doses of the drug could not be determined). In a double-blind, randomized, placebo-controlled multicenter study evaluating the clinical efficacy and safety of Ingavirin in a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections in 180 children aged 13-17 years, it was shown that Ingavirin was significantly superior to placebo, more quickly normalizing temperature body, stopping intoxication, fever, catarrhal phenomena. A double-blind, randomized, placebo-controlled multicenter study evaluating the clinical efficacy and safety of Ingavirin in a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections in 310 children aged 7-12 years has shown that Ingavirin is significantly more effective than placebo and provides a faster (on average 18 hours) decrease in body temperature and disappearance of symptoms of intoxication (sore throat, perspiration, pain when swallowing, nasal congestion, runny nose). |
| Pharmacological group | Antiviral and immunostimulating agent |
| Structure | 1 capsule contains: active substance: pentanedioic acid imidazolylethanamide (vitaglutam) in terms of 100% substance 60.00 mg; excipients: lactose monohydrate 60.00 mg, potato starch 23.72 mg, colloidal silicon dioxide (aerosil) 1.47 mg, magnesium stearate 1.47 mg; hard gelatin capsules: titanium dioxide E 171 1.0000%, iron dye yellow oxide E 172 1.0000%, gelatin up to 100%: the composition of the ink for the logo: shellac, propylene glycol E 1520, titanium dioxide E 171. |
| Registration number | LP-002968 |
| Date of state registration | 23.04.2019 |
| Manufacturer | Valenta Farm |
Reviews about Valenta Farm Ingavirin capsules 60 mg No. 10
Yandex.Market data
Advantages:
Good presentation
Disadvantages:
All liked it.
Comment:
March 2, 2020, Orenburg
Advantages:
On the 3rd day after administration, significant relief.
Disadvantages:
I do not have.
Comment:
It is very convenient that one capsule per day.
March 3, 2020, Novosibirsk
